The Catholic University of Korea Seoul St. Mary's Hospital

Researchers

• JLJongin Lee

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

  NCT07931547· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

  NCT07852637· Phase 4· Samsung Medical Center· Source

• Recruiting

  GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

  NCT07871435· Phase 1/2· GI Innovation, Inc.· Source

• Recruiting

  Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD

  NCT07770867· Neudive Inc.· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  Comparison of Office and Cuffless Ambulatory Blood Pressure-Guided Management in Patients With Hypertension

  NCT07770477· Seoul National University Hospital· Source

• Recruiting

  SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

  NCT07812805· Phase 1· SK Life Science, Inc.· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· SystImmune Inc.· Source

• Recruiting

  AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients

  NCT07792980· hy Co., LTD.· Source

• Recruiting

  Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration

  NCT07367282· Phase 4· Junyeop Lee· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

  NCT07668388· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

  NCT07154745· Phase 3· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery

  NCT07583134· Phase 4· Chang-Ik Yoon· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.

  NCT07679412· LucasBio· Source

• Recruiting

  Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

  NCT07415551· Phase 2· Yuhan Corporation· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial for Children With Autism Spectrum Disorder

  NCT07505290· Seoul National University Bundang Hospital· Source

• Recruiting

  A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

  NCT07187401· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.

  NCT07685457· LucasBio· Source

• Recruiting

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer

  NCT07853209· Phase 3· FutureChem· Source

• Recruiting

  Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

  NCT07240844· Phase 4· Seoul St. Mary's Hospital· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Enrolling by invitation

  Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery.

  NCT07380867· Seoul St. Mary's Hospital· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Recruiting

  Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

  NCT07670468· Phase 1/2· LucasBio· Source

• Recruiting

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

  NCT07220759· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Brenipatide in Participants With Alcohol Use Disorder

  NCT07219953· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Pilot Study on Efficacy of Digital Therapeutic NDTx-02 for Executive Function in Children and Adolescents With ADHD or ASD

  NCT07242625· Neudive Inc.· Source

• Recruiting

  A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

  NCT07219966· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

Showing 50 of 239.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma13 recruiting
• Lung cancer11 recruiting
• Colorectal cancer10 recruiting
• Childhood cancers7 recruiting
• Gastric and oesophageal cancer7 recruiting
• Type 2 diabetes7 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Coronary artery disease5 recruiting
• Heart failure5 recruiting
• Metastatic breast cancer5 recruiting
• Ovarian cancer5 recruiting
• Pancreatic cancer5 recruiting
• Bladder cancer4 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Cytomegalovirus infection4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Acute myeloid leukaemia3 recruiting
• Amyloidosis3 recruiting
• Cervical cancer3 recruiting
• High blood pressure3 recruiting
• Obesity3 recruiting
• Prostate cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Autism2 recruiting
• Chronic kidney disease2 recruiting
• COPD2 recruiting
• Depression2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Endometrial cancer2 recruiting
• Kidney cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Liver cirrhosis2 recruiting
• Macular degeneration2 recruiting
• Myelodysplastic syndromes2 recruiting
• Osteoarthritis2 recruiting
• Primary biliary cholangitis2 recruiting
• Alzheimer disease1 recruiting
• Atrial fibrillation1 recruiting
• Bronchiectasis1 recruiting
• Chronic spontaneous urticaria1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Haemophilia1 recruiting
• Head and neck cancer1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Insomnia1 recruiting
• Melanoma1 recruiting
• Psoriasis1 recruiting
• Rheumatoid arthritis1 recruiting
• Schizophrenia1 recruiting
• Sjögren's disease1 recruiting
• Stroke1 recruiting
• Tuberculosis1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  NCT06824168· Phase 2· Daiichi Sankyo· Source

• Completed

  Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

  NCT06969001· Phase 1· SCAI Therapeutics· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Pfizer· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Novo Nordisk A/S· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

  NCT06568042· Phase 2· Eli Lilly and Company· Source

• Completed

  To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD

  NCT06446193· Neudive Inc.· Source

• Completed

  Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

  NCT06490328· Phase 3· Dongkook Pharmaceutical Co., Ltd.· Source

• Completed

  DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

  NCT06406439· G2e Co., Ltd· Source

• Completed

  Clinical Trial to Assess the Safety and Efficacy of Intra-articular Injection Collagen Versus Hyaluronic Acid on Knee Osteoarthritis

  NCT07511777· Cellontech Co., Ltd.· Source

• Completed

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

  NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source

• Recruiting

  A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

  NCT06466785· Phase 3· Genexine, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment

  NCT06264557· Rowan· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Terminated

  A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

  NCT05781750· Phase 2· Kezar Life Sciences, Inc.· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

  NCT05867121· Phase 1· Genentech, Inc.· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children

  NCT06333964· Phase 3· Astrogen, Inc.· Source

• Completed

  A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases

  NCT05960708· Phase 1· Yuhan Corporation· Source

• Recruiting

  A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

  NCT05967689· Phase 2· Taiho Oncology, Inc.· Source

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder

  NCT05701345· Omni C&S· Source

• Completed

  A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

  NCT05804747· Daiichi Sankyo· Source

• Completed

  Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

  NCT06297434· Phase 2· J2H Biotech· Source

• Completed

  Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

  NCT05718375· Phase 2· Curacle Co., Ltd.· Source

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· NS Pharma, Inc.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Biomea Fusion Inc.· Source

• Completed

  A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

  NCT05642312· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

  NCT05263583· Phase 2· Cothera Bioscience, Inc· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke

  NCT05525949· Nunaps Inc· Source

• Completed

  A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

  NCT05361434· Ipsen· Source

• Terminated

  Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

  NCT05477615· Phase 2· Jin Hyoung Kang· Source

• Completed

  Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

  NCT07564726· Phase 3· Celltrion Pharm, Inc.· Source

• Completed

  A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

  NCT05133531· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

  NCT05236673· Boehringer Ingelheim· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

  NCT05352815· Phase 3· Novo Nordisk A/S· Source

Showing 50 of 125.

Conditions

Diseases this institution publishes on or runs trials for.

• Gastric and oesophageal cancer43 works · 17 trials
• Multiple myeloma34 works · 20 trials
• Mild cognitive impairment24 works · 2 trials
• Acute lymphoblastic leukaemia14 works · 8 trials
• High blood pressure7 works · 9 trials
• Myeloproliferative neoplasms7 works · 14 trials
• Sjögren's disease5 works · 4 trials
• Immune thrombocytopenia (ITP)4 works · 1 trial
• Aplastic anaemia4 works · 0 trials